Elevance Health, Inc.
Business
Elevance Health is a leading health insurer serving approximately 45.2 million medical members through managed care plans and related services. It offers risk-based and fee-based health plans across Individual, Employer Group, Medicaid, Medicare, and Federal Employee Program markets, with specialty services including pharmacy, dental, vision, and stop-loss insurance. The company operates through four reportable segments: Health Benefits (core insurance operations), CarelonRx (pharmacy services), Carelon Services (care delivery and analytics), and Corporate & Other, with operations across all 50 states, the District of Columbia, and Puerto Rico.
Summary from 10-K filed 2026-02-06
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Premiums | 164,639 | 144,166 | 142,854 | 133,229 | 117,373 | |
| Total operating revenue | 197,584 | 175,204 | 170,209 | 155,660 | 136,943 | |
| Net investment income | 2,194 | 2,051 | 1,825 | 1,485 | 1,378 | |
| Net losses on financial instruments | −653 | −445 | −694 | −550 | 318 | |
| Gain on sale of business | 0 | 201 | 0 | 0 | — | |
| Total revenues | 199,125 | 177,011 | 171,340 | 156,595 | 138,639 | |
| Benefit expense | 148,223 | 127,567 | 124,330 | 116,642 | 102,571 | |
| Cost of products sold | 21,178 | 19,750 | 17,293 | 13,035 | 10,895 | |
| Operating expense | 20,984 | 20,025 | 20,087 | 17,700 | 15,918 | |
| Interest expense | 1,402 | 1,185 | 1,030 | 851 | — | |
| Amortization of other intangible assets | 628 | 580 | 885 | 767 | 441 | |
| Total expenses | 192,415 | 169,107 | 163,625 | 148,995 | 130,644 | |
| Income before income tax expense | 6,710 | 7,904 | 7,715 | 7,600 | 7,995 | |
| Income tax expense | 1,049 | 1,933 | 1,724 | 1,712 | 1,846 | |
| Net income | 5,661 | 5,971 | 5,991 | 5,888 | 6,149 | |
| Net loss (gain) attributable to noncontrolling interests | 1 | 9 | −4 | 6 | 9 | |
| Shareholders net income | 5,662 | 5,980 | 5,987 | 5,894 | 6,158 | |
| Basic (in dollars per share) | 25.28 | 25.81 | 25.38 | 24.56 | 25.26 | |
| Diluted (in dollars per share) | 25.21 | 25.68 | 25.22 | 24.28 | 24.95 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 9,491 | 8,288 | 6,526 | 7,387 | 4,880 | |
| Fixed maturity securities (amortized cost of $25,773 and $25,879; allowance for credit losses of $21 and $6) | 25,884 | 25,201 | 29,614 | 25,952 | 26,267 | |
| Equity securities | 740 | 1,192 | 229 | 953 | 1,881 | |
| Premium receivables | 10,073 | 8,011 | 7,902 | 7,083 | 5,681 | |
| Self-funded receivables | 5,162 | 5,044 | 4,558 | 4,663 | 4,010 | |
| Other receivables | 6,307 | 6,016 | 5,405 | 4,298 | 3,749 | |
| Other current assets | 5,344 | 4,700 | 5,795 | 5,281 | 4,654 | |
| Assets held for sale | 0 | 490 | 0 | — | — | |
| Total current assets | 63,001 | 58,942 | 60,029 | 55,617 | 51,122 | |
| Fixed maturity securities (amortized cost of $1,116 and $1,049; allowance for credit losses of $0 and $0) | 1,121 | 1,035 | 876 | 752 | 632 | |
| Other invested assets | 10,839 | 9,749 | 6,107 | 5,685 | 5,225 | |
| Property and equipment, net | 4,679 | 4,652 | 4,359 | 4,316 | 3,919 | |
| Goodwill | 28,344 | 28,277 | 25,317 | 24,383 | 24,228 | |
| Other intangible assets | 11,200 | 12,094 | 10,273 | 10,315 | 10,615 | |
| Other noncurrent assets | 2,310 | 2,140 | 1,967 | 1,687 | 1,719 | |
| Total assets | 121,494 | 116,889 | 108,928 | 102,755 | 97,460 | |
| Medical claims payable | 17,084 | 15,746 | 16,111 | 15,596 | 13,518 | |
| Other policyholder liabilities | 3,632 | 4,204 | 5,600 | 5,933 | 5,521 | |
| Unearned income | 1,493 | 1,508 | 1,402 | 1,112 | 1,153 | |
| Accounts payable and accrued expenses | 7,322 | 6,927 | 6,910 | 5,607 | 4,970 | |
| Short-term borrowings | 150 | 365 | 225 | 265 | 275 | |
| Current portion of long-term debt | 1,099 | 1,649 | 1,649 | 1,500 | 1,599 | |
| Other current liabilities | 10,255 | 10,029 | 9,894 | 9,683 | 7,849 | |
| Liabilities held for sale | 0 | 153 | 0 | — | — | |
| Total current liabilities | 41,035 | 40,581 | 41,791 | 39,696 | 34,885 | |
| Long-term debt, less current portion | 30,797 | 29,218 | 23,246 | 22,349 | 21,157 | |
| Reserves for future policy benefits | 145 | 190 | 778 | 803 | 802 | |
| Deferred tax liabilities, net | 2,110 | 2,148 | 1,970 | 2,015 | 2,805 | |
| Other noncurrent liabilities | 3,381 | 3,326 | 1,738 | 1,562 | 1,683 | |
| Total liabilities | 77,468 | 75,463 | 69,523 | 66,425 | 61,332 | |
| Commitments and ContingenciesNote 14 | — | — | — | — | — | |
| Preferred stock, without par value, shares authorized - 100,000,000; shares issued and outstanding - none | 0 | 0 | 0 | 0 | 0 | |
| Common stock, par value $0.01, shares authorized - 900,000,000; shares issued and outstanding - 220,723,898 and 227,479,695 | 2 | 2 | 2 | 2 | 2 | |
| Additional paid-in capital | 8,938 | 8,911 | 8,868 | 9,084 | 9,148 | |
| Retained earnings | 35,393 | 33,549 | 31,749 | 29,647 | 27,088 | |
| Accumulated other comprehensive loss | −451 | −1,147 | −1,313 | −2,490 | −197 | |
| Total shareholders equity | 43,882 | 41,315 | 39,306 | 36,243 | 36,060 | |
| Noncontrolling interests | 144 | 111 | 99 | 87 | 68 | |
| Total equity | 44,026 | 41,426 | 39,405 | 36,330 | 36,140 | |
| Total liabilities and equity | 121,494 | 116,889 | 108,928 | 102,755 | 97,460 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Equity in net (earnings) losses of other invested assets | −398 | −1 | 33 | −293 | −562 | |
| Depreciation and amortization | 1,546 | 1,393 | 1,745 | 1,675 | 1,302 | |
| Deferred income taxes | −279 | −374 | −602 | −115 | 342 | |
| Impairment of property, equipment and right-of-use assets | 108 | 103 | 446 | 7 | 73 | |
| Share-based compensation | 276 | 191 | 289 | 264 | 255 | |
| Receivables, net | −2,526 | −683 | −1,762 | −2,510 | −2,138 | |
| Other invested assets | 0 | −78 | −79 | 11 | −70 | |
| Other assets | 57 | 824 | −675 | 133 | 41 | |
| Policy liabilities | 228 | −1,840 | 147 | 2,411 | 2,523 | |
| Unearned income | −15 | −113 | 290 | −42 | −113 | |
| Accounts payable and other liabilities | −720 | −272 | 1,640 | 824 | 719 | |
| Income taxes | −297 | 404 | −103 | −338 | 140 | |
| Other, net | −4 | 39 | 7 | −66 | 21 | |
| Net cash provided by operating activities | 4,290 | 5,808 | 8,061 | 8,399 | 8,364 | |
| Purchases of investments | −15,026 | −17,986 | −16,236 | −24,946 | −18,669 | |
| Proceeds from sale of investments | 13,324 | 16,547 | 10,596 | 11,988 | 10,269 | |
| Maturities, calls and redemptions from investments | 1,771 | 2,025 | 2,940 | 10,620 | 4,344 | |
| Changes in securities lending collateral | −385 | 73 | 78 | −301 | −956 | |
| Purchases of subsidiaries, net of cash acquired | 88 | −4,809 | −1,552 | −649 | −3,476 | |
| Proceeds from sales of subsidiaries, net of cash sold | 0 | 363 | 0 | 0 | — | |
| Purchases of property and equipment | −1,116 | −1,256 | −1,296 | −1,152 | −1,087 | |
| Other, net | 0 | −124 | −102 | −120 | −63 | |
| Net cash used in investing activities | −1,344 | −5,167 | −5,572 | −4,560 | −9,638 | |
| Proceeds from long-term borrowings, net issuance costs | 2,991 | 7,710 | 2,574 | 3,071 | 3,462 | |
| Repayments of long-term borrowings | −2,147 | −1,650 | −1,909 | −1,899 | −1,068 | |
| Proceeds from short-term borrowings | 1,505 | 275 | 225 | 1,365 | 1,375 | |
| Repayments of short-term borrowings | −1,720 | −135 | −265 | −1,675 | −1,050 | |
| Changes in securities lending payable | 386 | −75 | −77 | 302 | 956 | |
| Changes in bank overdrafts | 1,312 | −638 | 114 | 933 | −376 | |
| Repurchase and retirement of common stock | −2,605 | −2,900 | −2,676 | −2,316 | −1,900 | |
| Cash dividends | −1,529 | −1,508 | −1,395 | −1,229 | −1,104 | |
| Proceeds from issuance of common stock under employee stock plans | 79 | 221 | 152 | 182 | — | |
| Taxes paid through withholding of common stock under employee stock plans | −32 | −109 | −99 | −93 | −102 | |
| Other, net | 22 | 2 | 7 | 41 | 27 | |
| Net cash provided by (used in) financing activities | −1,738 | 1,193 | −3,349 | −1,318 | 423 | |
| Effect of foreign exchange rates on cash and cash equivalents | −5 | −6 | −1 | −14 | −10 | |
| Change in cash and cash equivalents | 1,203 | 1,828 | −861 | 2,507 | −861 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Elevance Health, Inc.'s CIK number?
Elevance Health, Inc.'s SEC CIK number is 0001156039 (1156039). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Elevance Health, Inc.'s SEC filings?
All of Elevance Health, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Elevance Health, Inc. last report earnings?
Elevance Health, Inc. (ELV) most recently filed an earnings 8-K with the SEC on Jul 15, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001156039-26-000058). This is Elevance Health, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Elevance Health, Inc.'s most recent earnings 8-K?
Elevance Health, Inc.'s latest earnings 8-K (Item 2.02) was filed Jul 15, 2026 under accession 0001156039-26-000058. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Elevance Health, Inc.'s latest earnings 8-K →
Look up any company's CIK number →